| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Effect of exchange rates on cash | 0 | 0 |
| Depreciation | 0 | 0 |
| Amortization of debt discount | 0 | - |
| Inducement expense | 0 | 0 |
| Change in fair value of contingent consideration | 0 | 0 |
| Right of use asset | 0 | 0 |
| Operating lease liability | 0 | 0 |
| Stock-based compensation | 20,783 | 20,783 |
| Change in fair value of derivative instrument-warrants | 4,055,133 | 4,102,408 |
| Accounts payable and accrued expenses | -110,786 | -22,693 |
| Prepaid expenses and other assets | -314,344 | -152,433 |
| Asset impairment loss | 402,746 | 402,746 |
| Net loss | -7,620,965 | -7,148,459 |
| Net cash used in operating activities | -2,938,745 | -2,492,782 |
| Investment in related party receivable | 0 | - |
| Investment in license agreement | 132,117 | 132,117 |
| Net cash used in investing activities | -132,117 | -132,117 |
| Proceeds from equity and debt issuance under spa, net of discount | 0 | - |
| Proceeds from the issuance of common stock and warrants, net | 9,000,000 | 9,000,000 |
| Equity issuance costs | 802,597 | 802,597 |
| Payments on notes payable | 3,211,871 | 3,054,517 |
| Net cash provided by financing activities | 4,985,532 | 5,142,886 |
| Net increase (decrease) in cash | 1,914,670 | 2,517,987 |
| Cash and cash equivalents at beginning of period | 406,408 | - |
| Cash and cash equivalents at end of period | 2,321,078 | - |
Hepion Pharmaceuticals, Inc. (CTRVP)
Hepion Pharmaceuticals, Inc. (CTRVP)